P27986 (P85A_HUMAN) Homo sapiens (Human)
Phosphatidylinositol 3-kinase regulatory subunit alpha UniProtKBInterProSTRINGInteractive Modelling
724 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3; Isoform 4; Isoform 5);
1 identical sequence: Homo sapiens: A0A2X0SFG1
It is possible new templates exist for this target since these models were created.
Available Structures
99 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Cryo-EM Structure of the KBTBD2-CUL3-Rbx1-p85a dimeric complex |
Heteromer P62877; Q13618; Q8IY47; | 6×ZN; | ||||
| Assess | ||||||
| Cryo-EM structure of p110alpha in complex with p85alpha inhibited by BYL-719 |
Heteromer P42336; | 1×1LT; | ||||
| Assess | ||||||
| PI 3-kinase alpha with nanobody 3-126 |
Heteromer P42336; | |||||
| Assess | ||||||
| PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 12). |
Heteromer P42336; | 1×1LT; 1×YQB; | ||||
| Assess | ||||||
| Crystal structure of PI3K complex with an inhibitor |
Heteromer P42336; | 1×84X; 1×SO4; | ||||
| Assess | ||||||
| Crystal Structure of p110alpha complexed with niSH2 of p85alpha and PI-103 |
Heteromer P42336; | 1×X6K; 2×SO4; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of PI3K complex with an inhibitor |
Heteromer P42336; | 1×84R; 1×P6G; 3×SO4; 2×GOL; | ||||
| Assess | ||||||
| Crystal Structure of p110alpha complexed with niSH2 of p85alpha |
Heteromer P42336; | 1×SO4; | ||||
| Assess | ||||||
| Crystal Structure of p110alpha complexed with niSH2 of p85alpha and compound 9d |
Heteromer P42336; | 1×XXK; 2×SO4; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of PI3K complex with an inhibitor |
Heteromer P42336; | 1×84U; 1×GOL; 1×SO4; | ||||
| Assess | ||||||
| Cryo-EM structure of PI3Kalpha in complex with compound 18 |
Heteromer P42336; | 1×L2V; | ||||
| Assess | ||||||
| Cryo-EM structure of PI3Kalpha in complex with compound 16 |
Heteromer P42336; | 1×7TZ; | ||||
| Assess | ||||||
| Cryo-EM structure of cancer-specific PI3Kalpha mutant H1047R in complex with BYL-719 |
Heteromer P42336; | 1×1LT; | ||||
| Assess | ||||||
| PI 3-kinase alpha with nanobody 3-142 |
Heteromer P42336; | |||||
| Assess | ||||||
| PI 3-kinase alpha with nanobody 3-142, crosslinked with DSG |
Heteromer P42336; | |||||
| Assess | ||||||
| Cryo-EM Structure of p110alpha in complex with p85alpha |
Heteromer P42336; | |||||
| Assess | ||||||
| Cryo-EM structure of PI3Kalpha in complex with compound 17 |
Heteromer P42336; | 1×7U5; | ||||
| Assess | ||||||
| CryoEM structure of human PI3K-alpha (P85/P110-H1047R) with QR-7909 binding at an allosteric site |
Heteromer P42336; | 1×UEX; | ||||
| Assess | ||||||
| CryoEM structure of human PI3K-alpha (P85/P110-H1047R) with QR-8557 binding at an allosteric site |
Heteromer P42336; | 1×UJ3; | ||||
| Assess | ||||||
| Human PI3K p85alpha/p110alpha H1047R bound to compound 3 |
Heteromer P42336; | 1×UJC; | ||||
| Assess | ||||||
| Human PI3K p85alpha/p110alpha H1047R bound to compound 2 |
Heteromer P42336; | 1×UIW; | ||||
| Assess | ||||||
| Human PI3K p85alpha/p110alpha H1047R bound to compound 1 |
Heteromer P42336; | 1×UE9; | ||||
| Assess | ||||||
| Crystal Structure of p110alpha in complex with niSH2 of p85alpha |
Heteromer P42336; | |||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragments 5 and 21 |
Heteromer P42336; | 1×AX7; 1×CAQ; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragments 20 and 26 |
Heteromer P42336; | 1×718; 2×CL; 1×SAL; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 10 |
Heteromer P42336; | 1×71N; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragments 6 and 24 |
Heteromer P42336; | 2×70W; 2×70V; 1×CL; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragments 17 and 27 |
Heteromer P42336; | 1×71A; 1×71B; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with diC4-PIP2 |
Heteromer P42336; | 2×PBU; 1×PO4; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragments 4 and 19 |
Heteromer P42336; | 1×CL; 1×70T; 1×2ZV; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 22 |
Heteromer P42336; | 1×71F; | ||||
| Assess | ||||||
| Human PI3K p85alpha/p110alpha |
Heteromer P42336; | |||||
| Assess | ||||||
| p85alpha/p110alpha heterodimer H1047R mutant |
Heteromer P42336; | |||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 29 |
Heteromer P42336; | 2×BHO; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragments 12 and 15 |
Heteromer P42336; | 2×71M; 1×LUZ; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragments 19 and 28 |
Heteromer P42336; | 1×71G; 1×ES3; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 14 |
Heteromer P42336; | 1×71L; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 18 |
Heteromer P42336; | 1×71K; | ||||
| Assess | ||||||
| Human PI3K p85alpha/p110alpha bound to RLY-2608 |
Heteromer P42336; | 1×XUZ; | ||||
| Assess | ||||||
| Crystal structure of PI3Kalpha in complex with fragments 7 and 11 |
Heteromer P42336; | 1×EPE; 1×70S; 2×FB1; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 13 |
Heteromer P42336; | 1×71J; | ||||
| Assess | ||||||
| Human PI3K p85alpha/p110alpha bound to compound 2 |
Heteromer P42336; | 1×UIW; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 8 |
Heteromer P42336; | 1×URF; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 23 |
Heteromer P42336; | 1×SOA; | ||||
| Assess | ||||||
| Structure of p110alpha/niSH2 - vector data collection |
Heteromer P42336; | 2×144; 3×SO4; | ||||
| Assess | ||||||
| Crystal Structure of a novel tetrahydropyrazolo[1,5-a]pyrazine in an engineered PI3K alpha |
Heteromer P42336; | 1×3K6; | ||||
| Assess | ||||||
| The co-structure of (R)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2-(1H-indol-4-yl)pyrimidin-4-yl)-… |
Heteromer P42336; | 1×8DV; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha |
Heteromer P42336; | 2×PO4; 1×GOL; | ||||
| Assess | ||||||
| Co-structure of Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and … |
Heteromer P42336; | 1×ZTV; 1×SO4; | ||||
| Assess | ||||||
| PI3K alpha in complex with an inhibitor |
Heteromer P42336; | 1×KVJ; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with the inhibitor NVP-BYL719 |
Heteromer P42336; | 1×1LT; 1×NA; | ||||
| Assess | ||||||
| Crystal structure of PI3K alpha with PI3K delta inhibitor |
Heteromer P42336; | 1×6CY; | ||||
| Assess | ||||||
| Co-crystal Structure of Lipid Kinase PI3K alpha with a selective phosphatidylinositol-3 kinase alph… |
Heteromer P42336; | 1×4Q2; | ||||
| Assess | ||||||
| The co-structure of N,N-dimethyl-4-[(6R)-6-methyl-5-(1H-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetrah… |
Heteromer P42336; | 1×3K6; | ||||
| Assess | ||||||
| The co-structure of 3-amino-6-(4-((1-(dimethylamino)propan-2-yl)sulfonyl)phenyl)-N-phenylpyrazine-2… |
Heteromer P42336; | 1×8DY; | ||||
| Assess | ||||||
| Co-structure Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform complex… |
Heteromer P42336; | 1×ZUO; | ||||
| Assess | ||||||
| Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse … |
Heteromer P42336; | 1×GOL; 1×5XV; | ||||
| Assess | ||||||
| Crystal structure of human T1061E PI3Kalpha in complex with its regulatory subunit and the inhibito… |
Heteromer P42336; | 1×MWF; 3×EDO; 1×PGE; 1×CL; | ||||
| Assess | ||||||
| PI3Ka H1047R co-crystal structure with inhibitors in two cryptic pockets (compounds 4 and 5). |
Heteromer P42336; | 1×YO4; 1×YOR; 1×YNZ; | ||||
| Assess | ||||||
| PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 4). |
Heteromer P42336; | 1×YO4; 1×YNZ; | ||||
| Assess | ||||||
| Co-crystal Structures of the Lipid Kinase PI3K alpha with Pan and Isoform Selective Inhibitors |
Heteromer P42336; | 1×SCN; 1×1LT; | ||||
| Assess | ||||||
| CryoEM structure of PI3Kalpha |
Heteromer P42336; | |||||
| Assess | ||||||
| STX-478, a Mutant-Selective, Allosteric Inhibitor bound to H1047R PI3Kalpha |
Heteromer P42336; | 10×EDO; 1×X3N; 1×ZWE; | ||||
| Assess | ||||||
| STX-478, a Mutant-Selective, Allosteric Inhibitor bound to PI3Kalpha |
Heteromer P42336; | 1×X3N; 1×ZWE; | ||||
| Assess | ||||||
| Crystal Structure of PI3Kalpha in complex with fragment 9 |
Heteromer P42336; | 1×HPP; | ||||
| Assess | ||||||
| PI 3-kinase alpha with nanobody 3-159 |
Heteromer P42336; | |||||
| Assess | ||||||
| Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha and the drug wortman… |
Heteromer P42336; | 1×KWT; | ||||
| Assess | ||||||
| Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha |
Heteromer P42336; | |||||
| Assess | ||||||
| PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket (compound 5). |
Heteromer P42336; | 1×YOR; 1×YNZ; | ||||
| Assess | ||||||
| Structure of a phosphoinositide 3-kinase alpha adaptor-binding domain (ABD) in a complex with the i… |
Heteromer P32871; | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A TRIFLUORO-ETHYL-PYRAZOL-PYROLOTRIAZINE INHIBITOR |
Heteromer O00329; | 1×9EM; | ||||
| Assess | ||||||
| Human PI3Kdelta in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)… |
Heteromer O00329; | 1×P5J; | ||||
| Assess | ||||||
| HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 3C |
Heteromer O00329; | 1×Y5Y; 1×EDO; 1×SO4; | ||||
| Assess | ||||||
| HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 28 |
Heteromer O00329; | 1×YA7; 1×CL; | ||||
| Assess | ||||||
| Human PI3Kdelta in complex with Compound 4-2 ((3S)-1'-(cyclopropanecarbonyl)-5-(quinoxalin-6-yl)spi… |
Heteromer O00329; | 1×P5V; | ||||
| Assess | ||||||
| Cryo-EM Structure of the KBTBD2-CUL3-Rbx1-p85a tetrameric complex |
Heteromer P62877; Q13618; Q8IY47; | 12×ZN; | ||||
| Assess | ||||||
| HUMAN PI3KDELTA IN COMPLEX WITH LASW1579 |
Heteromer O00329; | 1×7KA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF PI3K DELTA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4]… |
Heteromer O00329; | 1×85S; | ||||
| Assess | ||||||
| Structure of a human p110alpha/p85alpha complex |
Heteromer P42336; | |||||
| Assess | ||||||
| PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 7). |
Heteromer P42336; | 1×YQ2; 1×1LT; | ||||
| Assess | ||||||
| Crystal structure of p110alpha in complex with iSH2 of p85alpha and the inhibitor PIK-108 |
Heteromer P42337; | 2×P08; | ||||
| Assess | ||||||
| Crystal structure of the PI3-kinase p85 N-terminal SH2 domain in complex with c-Kit phosphotyrosyl … |
Heteromer P10721; | |||||
| Assess | ||||||
| nSH2 domain of p85-alpha subunit of phosphatidylinositol 3-kinase in complex with an actin peptide … |
Heteromer P68133; | 6×EDO; | ||||
| Assess | ||||||
| Molecular interactions of cytoplasmic region of CTLA-4 with SH2 domains of PI3-kinase |
Heteromer P16410; | |||||
| Assess | ||||||
| PI3K p85 C-terminal SH2 domain/CD28-derived peptide complex |
Heteromer P10747; | 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of the PI3-kinase p85 N-terminal SH2 domain in complex with PDGFR phosphotyrosyl … |
Heteromer P09619; | |||||
| Assess | ||||||
| PI3K p85 N-terminal SH2 domain/CD28-derived peptide complex |
Heteromer P10747; | 3×SO4; 1×GOL; | ||||
| Assess | ||||||
| PHOSPHATIDYLINOSITOL 3-KINASE, P85-ALPHA SUBUNIT: C-TERMINAL SH2 DOMAIN COMPLEXED WITH A TYR751 PHO… |
Heteromer P09619; | |||||
| Assess | ||||||
| NMR STUDY OF THE SH3 DOMAIN FROM FYN PROTO-ONCOGENE TYROSINE KINASE KINASE COMPLEXED WITH THE SYNTH… |
Heteromer P06241; | |||||
| Assess | ||||||
| NMR STUDY OF THE SH3 DOMAIN FROM FYN PROTO-ONCOGENE TYROSINE KINASE COMPLEXED WITH THE SYNTHETIC PE… |
Heteromer P06241; | |||||
| Assess | ||||||
| Pi3K alpha lipid kinase with Active Site Inhibitor | monomer | 3×4EL; | ||||
| Assess | ||||||
| STRUCTURE OF BCR-HOMOLOGY (BH) DOMAIN | monomer | |||||
| Assess | ||||||
| Crystal structure of the PI3-kinase p85 N-terminal SH2 domain | monomer | |||||
| Assess | ||||||
| PHOSPHATIDYLINOSITOL 3-KINASE, P85-ALPHA SUBUNIT: C-TERMINAL SH2 DOMAIN COMPLEXED WITH A TYR751 PHO… | monomer | |||||
| Assess | ||||||
| PHOSPHATIDYLINOSITOL 3-KINASE P85-ALPHA SUBUNIT SH3 DOMAIN, RESIDUES 1-85 | monomer | |||||
| Assess | ||||||
| PI3K SH3 domain in complex with a peptide ligand | monomer | |||||
| Assess | ||||||
| Crystal structure of PI3K SH3 | monomer | 1×SO4; | ||||
| Assess | ||||||
| STRUCTURE OF THE PI3K SH3 DOMAIN AND ANALYSIS OF THE SH3 FAMILY | monomer | |||||
| Assess | ||||||
| STRUCTURE OF THE PI3K SH3 DOMAIN AND ANALYSIS OF THE SH3 FAMILY | monomer | |||||
| Assess | ||||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 6mrp.1.A | homo-2-mer | 0.81 | 92.38 | |||
| Assess | ||||||
| 8h36.1.F | monomer | 0.74 | 100.00 | |||
| Assess | ||||||
| 2y3a.1.B | monomer | 0.60 | 73.36 | |||
| Assess | ||||||
9 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 8dcp.1.B | monomer | 0.70 | 99.53 | ||
| Assess | ||||||
| Isoform 2 | 2y3a.1.B | monomer | 0.61 | 73.36 | ||
| Assess | ||||||
| Isoform 3 | 8dcp.1.B | monomer | 0.71 | 99.76 | ||
| Assess | ||||||
| Isoform 3 | 2y3a.1.B | monomer | 0.61 | 73.36 | ||
| Assess | ||||||
| Isoform 4 | 6mrp.1.A | homo-2-mer | 0.81 | 92.23 | ||
| Assess | ||||||
| Isoform 4 | 8h36.1.F | monomer | 0.73 | 99.86 | ||
| Assess | ||||||
| Isoform 4 | 2y3a.1.B | monomer | 0.58 | 73.20 | ||
| Assess | ||||||
| Isoform 5 | 8h36.1.F | monomer | 0.77 | 100.00 | ||
| Assess | ||||||
| Isoform 5 | 2y3a.1.B | monomer | 0.64 | 73.97 | ||
| Assess | ||||||